← brief for 2026-08-26 · Slowing decline

Endothelin Receptor Antagonists in Resistant Hypertension and Proteinuric Kidney Disease: Receptor Strategy and Volume Management.

Key takeaways

This is a review article about endothelin receptor blockers, a class of blood pressure drug that also lowers protein in the urine. The authors walk through which drug, which dose, and what monitoring plan to use in people who have both hard-to-control blood pressure and chronic kidney disease. They give a lot of space to fluid buildup, the main side effect that limits these drugs. It sums up evidence that already exists, so there are no new results here.

Who did this work

Goldman CK · Goldman JM

Source

Article · PubMed, Blood pressure targets on losartan/ARB · 2026 Aug
https://pubmed.ncbi.nlm.nih.gov/42644854/